(68) administered FOS and glucomannan as treatments
C th: Liu lng glucosamine hng ngy theo trng lng c th D cc cht b sung khng b qun l cht ch, nhng vn c mt quy chun chung v liu lng glucosamine cho ngi ln, da trn trng lng c th
Gastrointestinal Side Effects are the predominant category of adverse reactions: Nausea affects approximately 12-24% of diabetes patients and up to 30% of weight management patients, typically most severe during the first few weeks of treatment or following dose increases Diarrhea occurs in 13-17% of diabetes patients and up to 24% of weight management patients Vomiting is reported by 6-10% of diabetes patients and up to 12% of weight management patients, particularly at higher doses Constipation affects 6-11% of diabetes patients and up to 17% of weight management patients Dyspepsia and abdominal pain occur in 6-9% of patients Decreased appetite is common and contributes to the medication's weight loss effects Gastroesophageal reflux disease (GERD) occurs in some patients, particularly at higher doses These gastrointestinal symptoms typically diminish over time as the body adapts to the medication
the National Key Scientific Instrument and Equipment Development Project (31627803)
Speed to market: for many sponsors, the fastest route to commercial impact remains a weekly injection with established PK/PD behavior and clearer risk management
This can address needs such as immune resilience, support during chronic illness, post-surgical recovery, or assistance in managing fatigue, inflammatory conditions, or recovery from intense physical activity
